X @Bloomberg

Public-health advocates and pharmaceutical investors aren’t always on the same page, but the FDA’s treatment of Moderna’s flu vaccine has both groups reeling. @Lisamjarvis explains why (via @opinion) https://t.co/zIFGbQeRlW ...